Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 tria

Whilst addition of cetuximab to chemotherapy has previously been shown to statistically improve progression-free survival, data from this long-term follow up study shows significant reduction in median overall survival (55.4 v 81.0months respectively; HR 1.45, 1.02–2.05; p=0.036)

SPS commentary:

In a related editorial, authors comment that although the addition of cetuximab to chemotherapy appears to improve overall survival in some patients with advanced, inoperable metastatic disease, its use in the perioperative setting in patients with operable disease confers a significant disadvantage in terms of overall survival and cetuximab should not be used in this setting.


The Lancet Oncology